Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06926621
PHASE2

A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I

Sponsor: Vertex Pharmaceuticals Incorporated

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate the long-term safety and tolerability, efficacy and pharmacokinetics of VX-670 in participants with Myotonic Dystrophy Type I (DM1).

Official title: An Open-label Extension Study Evaluating the Long-term Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-670 in Adult Subjects With Myotonic Dystrophy Type I

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

44

Start Date

2025-04-28

Completion Date

2029-01-30

Last Updated

2026-02-27

Healthy Volunteers

No

Interventions

DRUG

VX-670

Solution for intravenous administration.

Locations (11)

Wesley Research Institute

Auchenflower, Australia

Neuroscience Clinical Trials Unit, Alfred Brain

Melbourne, Australia

Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg - Pulmonology

Leuven, Belgium

Altasciences Montreal

Montreal, Canada

Montreal Neurological Institute-Hospital

Montreal, Canada

University of Ottawa

Ottawa, Canada

Universite Laval - Neurology

Québec, Canada

Hospital Universitario y Politecnico La Fe - Neurology

Valencia, Spain

Queen Elizabeth University Hospital - Neurology

Glasgow, United Kingdom

Leonard Wolfson Experimental Neurology Centre CRF

London, United Kingdom

Royal Hallamshire Hospital - Neurology

Sheffield, United Kingdom